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ABSTRACT 
The article presents the results of the research from position of forensic 
pharmacy concerning analysis of complaints about the pharmaceutical 
provision for privileged categories of patients in Ukraine. Analyzed world 
experience of the reimbursement system (reference pricing) in pharmaceutical 
provision for privileged categories of citizens comparing to existing system in 
Ukraine. Studied complaints of privileged contingents of patients concerning 
pharmaceutical supply in various health care facilities. Based on results created 
a matrix of complaints of privileged contingents of patients regarding 
unsatisfactory pharmaceutical provision. Based on the matrix of complaints, 
three regional lists of drugs were developed with the further development of 
organizational and legal measures to increase the level of pharmaceutical 
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Introduction. Benefits in Ukraine are provided on a categorical basis, according to the citizen's 
belonging to a certain privileged category depending on the social status or professional activity defined 
by law. Privileges are established for various purposes, as a reward to the state, to ensure an increased 
level of their social guarantees or as social support to ensure an adequate standard of living [1, 2]. 
In Ukraine, the main method of the state pharmaceutical privileged categories of patients 
remains public procurement for budget funds. In addition, at various times, a system of "preferential 
prescriptions", pilot projects to reimburse the cost of drugs, health insurance funds were introduced 
into practice. The ideas of insurance medicine have been actively discussed for a long time, but 
without any real steps for its implementation [3, 4]. 
Disadvantages of the state system of pharmaceutical provision of privileged contingents of 
patients in Ukraine include overstated costs for the purchase of drugs due to corruption schemes, lack 
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of market pricing, a huge number of formal requirements for tender documents, lack of long-term 
procurement planning by the state for manufacturing companies [5, 6]. 
That is why the search for alternative methods of pharmaceutical provision for privileged 
categories of patients at the expense of the state remains relevant. 
The world experience of the reimbursement system (reference pricing) is the most cost-effective 
and optimal, as it implements the principle of targeted subsidies. Reference pricing in the world is primarily 
aimed at establishing the level of reimbursement at the expense of the state, and retail prices are influenced 
by market mechanisms and the laws of free competition. This mechanism is used by the vast majority of 
countries and in practice has reduced health care costs by up to 50% [7, 8, 9]. 
For the first time in Ukraine, preferential pharmaceutical provision with elements of 
reimbursement of certain categories of patients with certain diseases was launched in 1998. 
Unfortunately, this area is developing less actively. Sufficient funds are not allocated for the 
pharmaceutical provision of beneficiaries with medicines. On the example of preferential 
pharmaceutical supply of medicines to people affected by the Chernobyl disaster, we can see how the 
financial support of the state went to a separate fund, which is replenished by direct mandatory 
payments from the population [10, 11]. 
In 2012, Ukraine launched the first pilot project to reimburse the cost of drugs for the 
treatment of people with hypertension. Despite some positive results at the initial stage of the project, 
such as lower antihypertensive drugs and positive indicators of real reimbursement to patients, today 
most pharmaceutical companies treat it with irritation rather than interest in participating. 
The main feature of the pharmaceutical supply of different contingents of patients is the social 
orientation. Therefore, it is necessary to actively develop the social potential of health care facilities 
(hospitals, clinics, pharmacies). The activities of the health care facilities include the implementation 
of costs, which are the basis for the formation of pricing policy for drugs. In market conditions, the 
main condition for effective pharmaceutical provision of privileged categories of patients is 
transparency, completeness, reliability, honesty and efficiency of information about the costs that form 
the cost of drugs [12, 13, 14]. 
Purpose of the research was to analyze the complaints of privileged contingents of patients 
for pharmaceutical supply in health care facilities (hospitals, clinics, pharmacies) from the position of 
forensic pharmacy and pharmaceutical law. 
Materials and Methods. The current research was carried out using the system approach 
during 2017–2020. The materials were questionnaires of employees of health departments among a 
number of regional state administrations, 58 health care institutions, 18 communal and private 
pharmacies that provide pharmaceutical benefits to privileged categories of patients. 
The information base of the study consisted of scientific works of foreign and domestic 
scientists on issues related to the organization of pharmaceutical business, management, forensic 
pharmacy, pharmaceutical supply, pricing policy for drugs [15, 16, 17]. 
Modern research methods were used: normative and legal, documentary, retrospective, 
bibliographic, systemic, forensic-pharmaceutical, sociological (questionnaire survey), comparative, 
marketing, graphic, mathematical analysis. Mathematical processing and statistical evaluation of data 
was performed using Microsoft Excel. 
The study of the article is a fragment of research work of the Kharkiv Medical Academy of 
Postgraduate Education on "Improving the organizational and legal procedure for providing patients with 
drugs from the standpoint of forensic pharmacy, organization and management of pharmacy" (state 
registration number 0116U003137, deadline 2016-2020) and "Pharmaceutical and medical law: integrated 
approaches to the drug circulation system from the standpoint of forensic pharmacy and organization of 
pharmaceutical business" (state registration number D/21U000031, deadline 2021-2026). 
Research results. Five thousand fifty complaints from privileged categories of patients about 
unsatisfactory pharmaceutical supply were processed according to a specially developed questionnaire [18]. 
Found that 61% of complaints of privileged patients (women accounted for 38%; men – 62%) 
were related to late or incomplete provision of prescription drugs. Violation of the rights of privileged 
categories of patients to receive drugs on discounted and free prescriptions of doctors was recorded in 
58% of complaints. 
At the preparatory stage of the study, a superficial analysis of the study materials was 
performed in order to eliminate improperly completed questionnaires and calculate the minimum 
number of them to obtain representative data of the study results according to the formula: 
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where  n – is the number of questionnaires; 
N – is the total number of respondents. 
In the course of the study, a matrix of complaints based on patient reports of unsatisfactory 
pharmaceutical supply of drugs of different clinical and pharmacological, classification and legal and 
nomenclature and legal groups was constructed (Fig. 1). 
Based on the matrix of complaints, appropriate lists of drugs were developed with the further 
development of organizational and legal measures to increase the level of pharmaceutical provision of 
privileged contingents of patients. 
Revealed that the reference pricing mechanism in the world is primarily aimed at establishing the 
level of reimbursement at the expense of the state, and retail prices are influenced by market mechanisms 
and the laws of free competition. This mechanism is used by the vast majority of EU countries and in 
practice has reduced health care costs by up to 50% depending on the state [19, 20, 21]. 
 
Fig. 1. Matrix of complaints of privileged contingents of patients regarding unsatisfactory 
pharmaceutical provision (source: own development) 
Discussion. In accordance to the ATC classification, the clinical and pharmacological 
distribution of drugs by five clinical and pharmacological groups, which appeared in the complaints of 
privileged contingents of patients [22]: 
A - Drugs affecting the digestive system and metabolism (9.5%) 
C - Drugs affecting the cardiovascular system (44.5%) 
D - Dermatological products (3.2%) 
M - Medications for musculoskeletal system (1.6%) 
N - Drugs acting on the nervous system (41.2%) 
Thus, the unsatisfactory level of pharmaceutical provision of privileged categories of patients 
among the drugs of clinical and pharmacological group C "Drugs that affect the cardiovascular 
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system" (44.5% of complaints); the share of complaints about drugs of group N acting on the nervous 
system is 41.2%; group A - 9.5%. 
Based on the study, three regional lists of drugs for pharmaceutical support of privileged 
categories of patients were compiled. 
List 1 included OTC drugs of the general group on complaints of privileged contingents of 
patients (Table 1). The biggest number of OTC drugs of the general group belongs to the ATC codes 
A and N (by 40% respectively). 
 
Table 1. Regional list one. OTC drugs of the general group on complaints of privileged 
contingents of patients (source: own development) 
No. INN ATC code Clinical and pharmacological group 
1 Fish oil oxidation products D08AX Antiseptics and disinfectants 
2 Silymarin A05BA03 Hepatoprotective drugs 
3 
Hyperici herba, Passiflorae herba, Valerianae 
radix, Crataegi folium cum flore, Lupuli flos, 
Melissae herba, Sambusi flos, Guaifenesin 
N05CM Sedatives 
4 
Sea buckthorn oil A02X Drugs that affect the digestive system 
and metabolism. Drugs for the 
treatment of acid-dependent diseases 
5 
Metamizole sodium, combinations with 
psycholeptics 
N02BB72 Analgesics antipyretics 
 
List two included prescription drugs of the general group on the complaints of privileged 
contingents of patients (Table 2). 
 
Table 2. Regional list two. Prescription drugs of the general group on complaints of privileged 
contingents of patients (source: own development) 
No. INN ATC code Clinical and pharmacological group 
1 
Deproteinized hemoderivative 
from calf blood 
A16AX Drugs that affect the digestive system and metabolic 
processes 
2 
Chlorpromazine N05AA01 Antipsychotic drugs. Phenothiazine derivatives with 
aliphatic structure 
3 
Amlodipine C08CA01 Selective calcium antagonists with a predominant effect 
on blood vessels. Dihydropyridine derivatives 
4 Atenolol C07AB03 Selective β-adrenoceptor blockers 
5 Metoprolol C07AB02 Selective β-adrenoceptor blockers 
6 
Barbiturates in combination 
with other drugs 
N05CB02 Hypnotics and sedatives. Barbiturates in combination 
with drugs of other groups 
7 Essential phospholipids A05BA Hepatotropic drugs 
8 Amiodarone C01BD01 Antiarrhythmic drugs, class III 
9 
Levodopa and decarboxylase 
inhibitor 
N04BA02 Antiparkinsonian drugs. Dopaminergic drugs. DOPA 
and derivatives. Levodopa with decarboxylase inhibitor 
10 Nalbuphine N02AF02 Analgesics. Opioids. Morphine derivatives 





A03DA02 Synthetic anticholinergics in combination with 
analgesics 
13 Ethanol D08AX08 Antiseptics and disinfectants 
 
Important to note, that among the prescription drugs of the general group on the complaints of 
privileged contingents of patients (Table 2) the first three positions on the unsatisfactory level of 
pharmaceutical supply were drugs with three ATC codes: "N" drugs acting on the nervous system 
(Aminazine, Valocordine, Levocome, etc.) - 30.8%; "C" drugs that affect the cardiovascular system 
(Amlodipine, Betaloc, Atenolol etc.) – 30.8%; "A" drugs that affect the digestive system and 
metabolism (Actovegine, Essentiale forte H, Renalgane) – 23.0%. 
As the place of ranking received the most complaints from the privileged contingents of 
patients regarding the pharmaceutical supply of drugs that affect the cardiovascular system, it was 
further analyzed, systematized, copied and compiled Regional List three – drugs of the general group 
affecting the cardiovascular system for complaints of different contingents of patients (Table 3). 
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Table 3. Regional list three. Drugs of the general group affecting the cardiovascular system on 
the complaints of privileged contingents of patients (source: own development) 
No. INN ATC code Clinical and pharmacological group 
Nomenclature and 
legal group 
1 2 3 4 5 
1 Amlodipine C08CA01 
Selective calcium antagonists with a 
predominant effect on blood vessels. 
Dihydropyridine derivatives 
By the F-1 recipe 
2 Atenolol C07AB03 Selective β-adrenoceptor blockers By the F-1 recipe 
3 Adenosine C01EB10 Cardiac drugs. Adenosine By the F-1 recipe 
4 Enalapril C09AA02 Angiotensin-converting enzyme inhibitors By the F-1 recipe 
5 Metoprolol C07AB02 Selective β-adrenoceptor blockers By the F-1 recipe 




C09BB03 Combined drugs of ACE inhibitors By the F-1 recipe 
8 Enalapril C09AA02 Angiotensin-converting enzyme inhibitors By the F-1 recipe 





Combined drugs of ACE inhibitors. 
Captopril and diuretics 
By the F-1 recipe 





Combined drugs of ACE inhibitors. 
Captopril and diuretics 
By the F-1 recipe 
13 Bisoprolol C07AB07 Selective β-adrenoceptor blockers By the F-1 recipe 
14 Amiodarone C01BD01 Antiarrhythmic drugs, class III By the F-1 recipe 
15 Lacidipine C08CA09 
Calcium channel blockers. Selective 
calcium channel blockers with a 
predominant effect on blood vessels 
By the F-1 recipe 
16 Lisinopril C09AA03 Angiotensin-converting enzyme inhibitors By the F-1 recipe 
17 Lisinopril C09AA03 Angiotensin-converting enzyme inhibitors By the F-1 recipe 
18 Betaxolol C07AB05 Selective β-adrenoceptor blockers By the F-1 recipe 
19 Losartan C09CA01 
Agents acting on the renin-angiotensin 
system. Simple drugs of angiotensin II 
receptor antagonists 
By the F-1 recipe 
20 Meldronium C01EB22 Cardiac drugs By the F-1 recipe 
21 Nebivolol C07AB12 Selective β-adrenoceptor blockers By the F-1 recipe 
22 Trimetazidine C01EB15 Cardiac drugs By the F-1 recipe 
23 Propafenone C01BC03 
Drugs for the treatment of heart disease. 
Antiarrhythmic drugs of the IC class 
By the F-1 recipe 
24 Amlodipine C08CA01 
Selective calcium antagonists with a 
predominant effect on blood vessels. 
Dihydropyridine derivatives 
By the F-1 recipe 
 
Based on the calculations, it was proved that the most unsatisfactory level of pharmaceutical supply 
received complaints about drugs Amlodipine, Atenolol, Adenosine, Enalapril, Amiodarone (95.8%). 
Conclusions. 1. It is substantiated that the main feature of pharmaceutical provision of 
privileged contingents of patients is social orientation. It is proved that it is necessary to actively 
develop the social potential of health care facilities in the format of transparency, completeness, 
reliability, and efficiency of information about the costs that form the cost of drugs. 
2. From the position of forensic pharmacy, five thousand fifty complaints were processed from 
privileged categories of patients regarding unsatisfactory pharmaceutical supply according to a 
specially developed questionnaire. 
3. In the course of the study, a matrix of complaints based on patient reports of unsatisfactory 
pharmaceutical supply of drugs of different clinical-pharmacological, classification-legal and 
nomenclature-legal groups was constructed. 
4. On the basis of the matrix of complaints, three regional lists of drugs were developed with 
the further development of organizational and legal measures to increase the level of pharmaceutical 
provision of privileged contingents of patients. 
5. It is noted that the reference mechanism of drug pricing is aimed at establishing the level of 
reimbursement at the expense of the state and reducing costs to 50% for pharmaceutical provision of 
privileged categories of patients. 
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